Proprietary AI analyst is now available
- Public Comps
- Promopharm
Promopharm Valuation Multiples
Discover revenue and EBITDA valuation multiples for Promopharm and similar public comparables like Vita Life Sciences, FitLife Brands, Venture Life Group, Hyundai Bioland Co and more.
Promopharm Overview
About Promopharm
Promotion Pharmaceutique du Maghreb is engaged in production, marketing, import and export of pharmaceuticals, parapharmaceuticals, dermopharmaceuticals and cosmetics.
Founded
1985
HQ

Employees
N/A
Website
Financials (FY)
EV
$92M
Valuation Multiples
Start free trialPromopharm Financials
Promopharm reported last fiscal year revenue of $97M and EBITDA of $12M.
In the same fiscal year, Promopharm generated $42M in gross profit, $12M in EBITDA, and $6M in net income.
Promopharm P&L
In the most recent fiscal year, Promopharm reported revenue of $97M and EBITDA of $12M.
Promopharm is profitable as of last fiscal year, with gross margin of 43%, EBITDA margin of 12%, and net margin of 6%.
Financial data powered by Morningstar, Inc.
Promopharm Stock Performance
Promopharm has current market cap of $92M, and enterprise value of $92M.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $92M | $92M | - | - | - | - | - |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPromopharm Valuation Multiples
Promopharm trades at 0.9x EV/Revenue multiple, and 7.8x EV/EBITDA.
Promopharm Financial Valuation Multiples
As of June 11, 2026, Promopharm has market cap of $92M and EV of $92M.
Promopharm has a P/E ratio of 15.4x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Promopharm Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Promopharm Margins & Growth Rates
In the most recent fiscal year, Promopharm reported gross margin of 43%, EBITDA margin of 12%, and net margin of 6%.
Promopharm Margins
Promopharm Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Promopharm Operational KPIs
Data powered by FactSet, Inc. and Morningstar, Inc.
Promopharm Competitors
Promopharm competitors include Vita Life Sciences, FitLife Brands, Venture Life Group, Hyundai Bioland Co, Enzymatica, Chong Kun Dang Holdings, Hofseth BioCare, Biome Australia, Provexis and Valbiotis.
Most Promopharm public comparables operate across Nutraceuticals & Cosmeceuticals.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.1x | - | 6.7x | - | |||
| 1.8x | 1.5x | 10.2x | 9.7x | |||
| 1.8x | 1.3x | 11.0x | 7.9x | |||
| 0.8x | - | 5.5x | - | |||
| 10.9x | 10.9x | (13.4x) | - | |||
| 0.6x | - | 4.8x | - | |||
| 3.1x | - | (11.1x) | - | |||
| 3.3x | 2.4x | 94.4x | 16.3x | |||
This data is available for Pro users. Sign up to see all Promopharm competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Promopharm
| When was Promopharm founded? | Promopharm was founded in 1985. |
| Where is Promopharm headquartered? | Promopharm is headquartered in Morocco. |
| Is Promopharm publicly listed? | Yes, Promopharm is a public company listed on Casablanca Stock Exchange. |
| What is the stock symbol of Promopharm? | Promopharm trades under PRO ticker. |
| When did Promopharm go public? | Promopharm went public in 2007. |
| Who are competitors of Promopharm? | Promopharm main competitors include Vita Life Sciences, FitLife Brands, Venture Life Group, Hyundai Bioland Co, Enzymatica, Chong Kun Dang Holdings, Hofseth BioCare, Biome Australia, Provexis, Valbiotis. |
| What is the current market cap of Promopharm? | Promopharm's current market cap is $92M. |
| What is the current revenue of Promopharm? | Promopharm's last fiscal year revenue is $97M. |
| What is the current EV/Revenue multiple of Promopharm? | Current revenue multiple of Promopharm is 0.9x. |
| Is Promopharm profitable? | No, Promopharm is not profitable. |
| How many companies Promopharm has acquired to date? | Promopharm hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Promopharm has invested to date? | Promopharm hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Promopharm
Lists including Promopharm
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.